Pulmatrix Net Income
| PULM Stock | USD 2.38 0.07 2.86% |
As of the 11th of February 2026, Pulmatrix holds the Variance of 34.44, coefficient of variation of (712.93), and Risk Adjusted Performance of (0.10). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pulmatrix, as well as the relationship between them. Please check Pulmatrix information ratio and skewness to decide if Pulmatrix is priced some-what accurately, providing market reflects its current price of 2.38 per share. Please also confirm Pulmatrix jensen alpha, which is currently at (0.78) to check out the company can sustain itself at a future point.
Pulmatrix Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 22.4001 | Revenue | Earnings Share (1.71) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.6 M | -9 M | |
| Net Loss | -11 M | -11.5 M | |
| Net Loss | -17 M | -17.8 M | |
| Net Loss | (2.36) | (2.47) | |
| Net Income Per E B T | 0.81 | 0.72 |
Pulmatrix | Net Income | Build AI portfolio with Pulmatrix Stock |
Evaluating Pulmatrix's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Pulmatrix's fundamental strength.
Latest Pulmatrix's Net Income Growth Pattern
Below is the plot of the Net Income of Pulmatrix over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pulmatrix financial statement analysis. It represents the amount of money remaining after all of Pulmatrix operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pulmatrix's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmatrix's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.56 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Pulmatrix Net Income Regression Statistics
| Arithmetic Mean | (14,152,374) | |
| Coefficient Of Variation | (66.04) | |
| Mean Deviation | 8,023,722 | |
| Median | (18,056,000) | |
| Standard Deviation | 9,346,407 | |
| Sample Variance | 87.4T | |
| Range | 27.8M | |
| R-Value | (0.25) | |
| Mean Square Error | 87.5T | |
| R-Squared | 0.06 | |
| Significance | 0.34 | |
| Slope | (458,517) | |
| Total Sum of Squares | 1397.7T |
Pulmatrix Net Income History
Other Fundumenentals of Pulmatrix
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Pulmatrix Net Income component correlations
Pulmatrix Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pulmatrix is extremely important. It helps to project a fair market value of Pulmatrix Stock properly, considering its historical fundamentals such as Net Income. Since Pulmatrix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pulmatrix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pulmatrix's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Pulmatrix 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pulmatrix's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pulmatrix.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Pulmatrix on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Pulmatrix or generate 0.0% return on investment in Pulmatrix over 90 days. Pulmatrix is related to or competes with Dare Bioscience, Hoth Therapeutics, Aspire BioPharma, Palisade Bio, Aditxt, Curis, and FibroBiologics Common. Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat r... More
Pulmatrix Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pulmatrix's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pulmatrix upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 51.95 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 6.62 |
Pulmatrix Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pulmatrix's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pulmatrix's standard deviation. In reality, there are many statistical measures that can use Pulmatrix historical prices to predict the future Pulmatrix's volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (1.44) | |||
| Treynor Ratio | 1.24 |
Pulmatrix February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | 1.25 | |||
| Mean Deviation | 3.24 | |||
| Coefficient Of Variation | (712.93) | |||
| Standard Deviation | 5.87 | |||
| Variance | 34.44 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (1.44) | |||
| Treynor Ratio | 1.24 | |||
| Maximum Drawdown | 51.95 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 6.62 | |||
| Skewness | (3.10) | |||
| Kurtosis | 20.84 |
Pulmatrix Backtested Returns
Pulmatrix maintains Sharpe Ratio (i.e., Efficiency) of -0.16, which implies the firm had a -0.16 % return per unit of risk over the last 3 months. Pulmatrix exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pulmatrix's Risk Adjusted Performance of (0.10), variance of 34.44, and Coefficient Of Variation of (712.93) to confirm the risk estimate we provide. The company holds a Beta of -0.67, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Pulmatrix are expected to decrease at a much lower rate. During the bear market, Pulmatrix is likely to outperform the market. At this point, Pulmatrix has a negative expected return of -0.96%. Please make sure to check Pulmatrix's jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Pulmatrix performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.23 |
Weak reverse predictability
Pulmatrix has weak reverse predictability. Overlapping area represents the amount of predictability between Pulmatrix time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pulmatrix price movement. The serial correlation of -0.23 indicates that over 23.0% of current Pulmatrix price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.23 | |
| Spearman Rank Test | -0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pulmatrix Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pulmatrix reported net income of (9.56 Million). This is 102.8% lower than that of the Pharmaceuticals sector and 113.65% lower than that of the Health Care industry. The net income for all United States stocks is 101.67% higher than that of the company.
Pulmatrix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pulmatrix's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pulmatrix could also be used in its relative valuation, which is a method of valuing Pulmatrix by comparing valuation metrics of similar companies.Pulmatrix is currently under evaluation in net income category among its peers.
Pulmatrix Current Valuation Drivers
We derive many important indicators used in calculating different scores of Pulmatrix from analyzing Pulmatrix's financial statements. These drivers represent accounts that assess Pulmatrix's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pulmatrix's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 20.5M | 13.4M | 6.8M | 25.5M | 29.3M | 22.1M | |
| Enterprise Value | (31.1M) | (21.4M) | (3.6M) | 16.0M | 14.4M | 15.1M |
Pulmatrix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pulmatrix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pulmatrix's managers, analysts, and investors.Environmental | Governance | Social |
Pulmatrix Institutional Holders
Institutional Holdings refers to the ownership stake in Pulmatrix that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Pulmatrix's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pulmatrix's value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 110.8 K | Jones Financial Companies Lllp | 2025-06-30 | 0.0 | Sbi Securities Co Ltd | 2025-06-30 | 60.6 K | Blackrock Inc | 2025-06-30 | 55.3 K | Vanguard Group Inc | 2025-06-30 | 47 K | Geode Capital Management, Llc | 2025-06-30 | 41.1 K | State Street Corp | 2025-06-30 | 13.9 K | Ubs Group Ag | 2025-06-30 | 5.5 K | Tower Research Capital Llc | 2025-06-30 | 408 | Citigroup Inc | 2025-06-30 | 90.0 | Bank Of America Corp | 2025-06-30 | 36.0 |
Pulmatrix Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | (536.38 K) | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Insiders | 0.66 % | ||||
| Shares Owned By Institutions | 9.20 % | ||||
| Number Of Shares Shorted | 7.04 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 2,995 X | ||||
| Revenue | 7.81 M | ||||
| Gross Profit | (7.16 M) | ||||
| EBITDA | (7.04 M) | ||||
| Net Income | (9.56 M) | ||||
| Cash And Equivalents | 42.91 M | ||||
| Cash Per Share | 12.67 X | ||||
| Total Debt | 996 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.19 X | ||||
| Book Value Per Share | 1.30 X | ||||
| Cash Flow From Operations | (10.72 M) | ||||
| Short Ratio | 0.20 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.71 | ||||
| Market Capitalization | 8.98 M | ||||
| Total Asset | 9.94 M | ||||
| Retained Earnings | (297.16 M) | ||||
| Working Capital | 8.99 M | ||||
| Current Asset | 8.34 M | ||||
| Current Liabilities | 4.11 M | ||||
| Net Asset | 9.94 M |
About Pulmatrix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.